Skip to content
TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo
  • About Us
    • Meet TaiRx
    • Vision
    • Innovation
    • Management Team
    • Scientific Advisory Committee
    • Board of Directors
  • Product Pipeline
    • CVM-1118
    • Rexis®
    • TRX-711
    • TRX-NOC
    • TRX-920
    • TRX-105
  • Market Product
  • News
  • Contact Us
  • enEnglish
    • zh-hant繁體中文
News jeff 2018-05-31T11:46:02+00:00

News

Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.

2020/12/9 Andrew Lin [...]

Chang Lisa 2021-01-15T18:57:12+00:00 December 9th, 2020|News|
Read More

TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.

2020/12/1 Having been [...]

Chang Lisa 2021-01-15T19:03:57+00:00 December 1st, 2020|News|
Read More

TaiRx successfully raised 504 million NTD in capital.

2020/11/27 To enrich [...]

Chang Lisa 2020-12-25T14:44:46+00:00 November 27th, 2020|News|
Read More

TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region

2019/8/30 World-renowned professional [...]

Chang Lisa 2019-09-16T11:48:11+00:00 August 30th, 2019|News|
Read More

TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.

2019/1/2 TaiRx, Inc. [...]

Chang Lisa 2019-09-16T11:47:49+00:00 January 2nd, 2019|News|
Read More
12Next

TEL: +886-2-2653-5007
FAX: +886-2-2653-5008
EMAIL: contact@trx.com.tw

TaiRx, Inc.
6F-1, No. 66, San-Chung Rd.
Nankang Dist., Taipei 115602, Taiwan

Copyright© 2018 TaiRx, Inc. | Web Design:Wakeup